Sign In
Buy TOVX
$0.288
+0.0020 (+0.699%)
At Close: Jun 03, 2026
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
04:30pm, Tuesday, 05'th May 2026
– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –
- Los análisis de la respuesta tumoral, los biomarcadores y los subgrupos del ensayo clínico VIRAGE de Fase 2b respaldan el mecanismo de acción inmunomediado de VCN-01 y demuestran una mejora en lo
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients a
- Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC - - Comb
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2025
06:26am, Friday, 13'th Mar 2026
- Avances en el desarrollo clínico del VCN-01 para el adenocarcinoma ductal pancreático y el retinoblastoma - - Concesión de la licencia de SYN-020 a Rasayana Therapeutics para su desarrollo en mú
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 4.9% – Time to Sell?
03:46am, Thursday, 15'th Jan 2026
Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report)'s stock price traded down 4.9% on Wednesday. The stock traded as low as $0.1926 and last traded at $0.2007. 2,809,196 shares were traded d
Why Is Theriva Biologics Stock Gaining Monday?
11:41am, Monday, 29'th Dec 2025
Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Phase 3 trial of VCN-01 for PDAC treatment.
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC , including sample s
Theriva Biologics (NYSEAMERICAN:TOVX) Trading 5.2% Higher – Here’s Why
04:06am, Wednesday, 24'th Dec 2025
Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report)'s share price was up 5.2% during mid-day trading on Tuesday. The stock traded as high as $0.2187 and last traded at $0.2029. Approximately
Theriva Biologics (NYSEAMERICAN:TOVX) Trading 3.4% Higher – Still a Buy?
02:45am, Wednesday, 26'th Nov 2025
Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report) shares were up 3.4% on Tuesday. The company traded as high as $0.2450 and last traded at $0.2388. Approximately 1,538,827 shares changed h
Short Interest in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Grows By 61.7%
01:27am, Sunday, 02'nd Nov 2025
Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 38
Theriva Biologics Provides Response to Unusual Market Action
02:31pm, Friday, 24'th Oct 2025
ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designe
Theriva™ Biologics anuncia una operación de incentivo de warrants por un importe bruto de 4 millones de dólares
07:23pm, Thursday, 16'th Oct 2025
ROCKVILLE, Maryland, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), («Theriva» o la «empresa»), una empresa diversificada de fase clínica que desarrolla terapias dise�
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
08:11am, Thursday, 16'th Oct 2025
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designe
- Preclinical data for VCN-12, the next candidate from Theriva's VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects -
